Epilepsy - Comprehensive Medical Student Review
1. Definition
Epilepsy is a disease of the brain defined by the 2014 ILAE criteria as any ONE of:
- At least two unprovoked (or reflex) seizures occurring >24 hours apart
- One unprovoked seizure with a probability of further seizures ≥60% over the next 10 years (e.g., after a single seizure with a structural lesion on MRI, or epileptiform EEG)
- Diagnosis of an epilepsy syndrome
Key distinction: A seizure is a single event of abnormal excessive hypersynchronous neuronal activity. Epilepsy is the underlying disease predisposing to recurrent seizures. Provoked seizures (e.g., alcohol withdrawal, hypoglycemia, hyponatremia) are not epilepsy.
- Bradley and Daroff's Neurology in Clinical Practice
2. Pathophysiology
The Paroxysmal Depolarizing Shift (PDS)
The fundamental cellular event is the paroxysmal depolarizing shift - a massive, prolonged depolarization of neurons in a seizure focus driven by:
- AMPA- and NMDA-type glutamate receptor-channels (excitatory input)
- Voltage-gated Ca²⁺ channels (gCa) amplifying depolarization
- Followed by hyperpolarization via: GABA-A receptors (Cl⁻), GABA-B receptors (K⁺), and Ca²⁺-activated K⁺ channels (gK)
The PDS represents exaggerated excitation in a seizure focus. The afterhyperpolarization normally limits seizure duration. When it fails, seizures propagate.
The conductances underlying the PDS: AMPA and NMDA drive depolarization; GABA and gK drive the afterhyperpolarization. - Eric Kandel, Principles of Neural Science, 6th Ed.
Seizure Spread
- Focal seizure: Starts in a focus, spreads via intrahemispheric fibers (1), to homotopic contralateral cortex via corpus callosum (2), and to subcortical centers (3)
- Secondary generalization: Thalamic involvement (4) propagates activity to both hemispheres simultaneously
- Primary generalized seizure: Both hemispheres activated simultaneously from onset via thalamocortical circuits (Panel B above)
Eric Kandel, Principles of Neural Science, 6th Ed.
Imbalance Summary (Exam High-Yield)
| Mechanism | Result |
|---|
| ↑ Glutamate (AMPA/NMDA) | ↑ Excitation → seizure |
| ↓ GABA-A/B function | ↓ Inhibition → seizure |
| Na⁺ channel dysfunction | Repetitive firing |
| T-type Ca²⁺ channel ↑ | Absence seizures (thalamocortical circuits) |
3. ILAE Classification (2017) - Three Levels
The 2017 ILAE framework has three levels. Classification at all three is ideal but not always achievable.
Level 1: SEIZURE TYPE
↓
Level 2: EPILEPSY TYPE
↓
Level 3: EPILEPSY SYNDROME
+ ETIOLOGY (at every level)
+ COMORBIDITIES
Level 1 - Seizure Types
A. Focal-Onset Seizures (arise from one hemisphere)
- Focal aware (previously "simple partial") - consciousness preserved
- Focal impaired awareness (previously "complex partial") - consciousness impaired
- Focal to bilateral tonic-clonic (previously "secondarily generalized")
Focal features by lobe of origin:
| Lobe | Typical Features |
|---|
| Temporal | Aura (déjà vu, rising epigastric sensation), automatisms (lip-smacking, hand fumbling), post-ictal confusion |
| Frontal | Motor signs, brief seizures, nocturnal, may generalize rapidly |
| Parietal | Sensory symptoms, tingling, numbness |
| Occipital | Visual hallucinations (lights, colors) |
B. Generalized-Onset Seizures (both hemispheres from onset)
| Type | Key Features |
|---|
| Absence (typical) | Sudden behavioral arrest + staring, 3-20 sec, no post-ictal phase, 3 Hz spike-wave on EEG |
| Absence (atypical) | Slower onset/offset, often in Lennox-Gastaut syndrome |
| Myoclonic | Brief (<100 ms) involuntary muscle jerks; morning predominance in JME |
| Tonic | Sustained muscle contraction, trunk/limb stiffening |
| Clonic | Rhythmic jerking movements |
| Tonic-clonic (GTC) | Tonic phase → clonic phase; post-ictal drowsiness/confusion |
| Atonic | Sudden loss of muscle tone ("drop attacks") |
| Epileptic spasms | West syndrome; flexion/extension of trunk |
C. Unknown Onset
Level 2 - Epilepsy Types
- Focal epilepsy
- Generalized epilepsy
- Combined generalized and focal (e.g., Dravet syndrome)
- Unknown
Level 3 - Common Epilepsy Syndromes (High-Yield)
| Syndrome | Age of Onset | Seizure Type | EEG | Key Feature |
|---|
| Childhood Absence Epilepsy (CAE) | 4-8 yr | Typical absence | 3 Hz generalized spike-wave | Hyperventilation triggers; ethosuximide/valproate |
| Juvenile Myoclonic Epilepsy (JME) | Adolescence | Myoclonic + GTC ± absence | 4-6 Hz polyspike-wave; morning | Lifelong treatment usually needed |
| Benign Rolandic Epilepsy (BECTS) | 3-13 yr | Focal sensorimotor face/arm | Centrotemporal spikes | Often outgrown by puberty |
| West Syndrome | 3-7 months | Epileptic spasms (clusters) | Hypsarrhythmia | ACTH/vigabatrin treatment |
| Lennox-Gastaut Syndrome | 1-7 yr | Multiple types (tonic, atonic, absence) | Slow (<2.5 Hz) spike-wave | Developmental regression, refractory |
| Dravet Syndrome | <1 yr | Febrile + afebrile GTC | Polyspike-wave | SCN1A mutation; sodium channel blockers WORSEN it |
| Temporal Lobe Epilepsy (TLE) | Any | Focal impaired awareness + GTC | Temporal spikes/sharp waves | Most common adult focal epilepsy; mesial TLE with hippocampal sclerosis |
4. Etiology
The ILAE 2017 framework emphasizes identifying the etiology at every classification level:
| Etiology Category | Examples |
|---|
| Structural | Hippocampal sclerosis, cortical dysplasia, tumors, stroke, trauma, encephalitis |
| Genetic | SCN1A (Dravet), KCNQ2, DEPDC5, chromosomal (Down, Angelman) |
| Infectious | Neurocysticercosis, HSV encephalitis, HIV |
| Metabolic | Pyridoxine deficiency, mitochondrial disease, PKU |
| Immune | Anti-NMDAR encephalitis, LGI1, CASPR2 antibodies |
| Unknown | ~50% of all epilepsies |
5. Clinical Assessment & Diagnosis
History (most important diagnostic tool)
- Full description of the episode (from witness): onset, progression, duration
- Pre-ictal aura (points to focal onset)
- Ictal features: automatisms, motor activity, eye deviation, head turn
- Post-ictal: confusion (Todd's paralysis, aphasia), duration
- Provoking factors, sleep deprivation, alcohol, medications
- Family history, birth history, febrile seizures
EEG (Electroencephalogram)
- Interictal EEG: Spike-and-wave discharges between seizures
- 3 Hz generalized spike-wave = absence epilepsy
- Centrotemporal spikes = BECTS
- Hypsarrhythmia = West syndrome
- Focal temporal spikes = TLE
- Ictal EEG: Rhythmic activity corresponding to clinical seizure
- EEG is normal in 50% of patients with epilepsy on a routine interictal recording
- Sleep deprivation, hyperventilation, and photic stimulation are activation procedures
- EEG bands: delta (0.5-4 Hz), theta (4-7 Hz), alpha (8-13 Hz), beta (13-30 Hz)
Neuroimaging
- MRI brain (preferred over CT): Structural causes (hippocampal sclerosis, tumors, dysplasia)
- FLAIR and T2 sequences most sensitive for cortical abnormalities
- CT head: Used acutely to exclude hemorrhage/mass
Initial Investigations for New-Onset Seizures
- Blood glucose, electrolytes (Na⁺, Ca²⁺, Mg²⁺), renal/liver function, FBC
- Toxicology screen
- EEG
- MRI brain
- LP if encephalitis/meningitis suspected
6. Antiseizure Medications (ASMs) - High-Yield Table
| Drug | Mechanism | Indications | Key Adverse Effects |
|---|
| Valproic acid | Na⁺ channel + GABA ↑ + T-Ca²⁺ ↓ + NMDA ↓ (multiple) | Focal + generalized + absence | Hepatotoxicity, teratogen (neural tube defects), weight gain, thrombocytopenia, pancreatitis |
| Phenytoin | Na⁺ channel inhibitor | Focal + generalized | Zero-order kinetics, gingival hyperplasia, hirsutism, nystagmus, ataxia, Stevens-Johnson syndrome; hepatic enzyme inducer |
| Carbamazepine | Na⁺ channel inhibitor | Focal + GTC; TN | Hyponatremia (SIADH), diplopia, SJS (HLA-B*1502 in Asian patients); enzyme inducer |
| Oxcarbazepine | Na⁺ channel inhibitor | Focal seizures | Less enzyme induction than CBZ; hyponatremia |
| Lamotrigine | Na⁺ channel inhibitor | Focal + generalized | Rash (slow titration prevents SJS); slow dose escalation needed; enzyme inducer |
| Levetiracetam | SV2A modulation | Focal + generalized | Mood disturbance, irritability, psychosis; minimal drug interactions |
| Brivaracetam | SV2A modulation (higher affinity) | Focal + generalized | Less psychiatric side effects than levetiracetam |
| Ethosuximide | T-type Ca²⁺ channel ↓ | Absence seizures only | GI upset, headache; NOT effective for focal seizures |
| Topiramate | Na⁺ + GABA ↑ + AMPA ↓ + Ca²⁺ ↓ | Focal + generalized | Cognitive impairment ("Dopamax"), nephrolithiasis, weight loss, glaucoma |
| Phenobarbital | GABA-A potentiation | Focal + generalized | Sedation, cognitive effects; enzyme inducer |
| Lacosamide | Na⁺ channel (slow inactivation) | Focal + generalized | PR interval prolongation |
| Zonisamide | Na⁺ + Ca²⁺ channels | Focal + generalized | Nephrolithiasis, cognitive effects, weight loss |
| Vigabatrin | Irreversible GABA-T inhibitor | Infantile spasms (1st-line); focal | Irreversible peripheral visual field loss |
| Perampanel | AMPA receptor antagonist | Focal + generalized | Dizziness, psychiatric effects |
| Gabapentin/Pregabalin | α2δ Ca²⁺ channel subunit | Focal seizures (adjunct) | Sedation, weight gain |
Adams and Victor's Principles of Neurology, 12th Ed.; Eric Kandel, Principles of Neural Science, 6th Ed.
Drug Selection Principles (High-Yield)
- Absence epilepsy: Ethosuximide (1st-line pure absence), Valproate (if GTC also present)
- Focal epilepsy: Carbamazepine or Lamotrigine (1st-line)
- JME: Valproate (most effective), Lamotrigine, Levetiracetam
- Dravet syndrome: AVOID Na⁺ channel blockers (phenytoin, carbamazepine, lamotrigine - they worsen); use valproate, clobazam, topiramate
- Infantile spasms (West syndrome): ACTH or prednisolone (1st-line); vigabatrin (especially in TSC)
- Women of childbearing age: Avoid valproate if possible (teratogenicity); lamotrigine preferred
7. Management Principles
When to Start Treatment
- After two unprovoked seizures - start ASM
- After one seizure with high recurrence risk (structural lesion, epileptiform EEG, epilepsy syndrome)
- After one seizure alone - treatment not automatically required
Monotherapy First
- Start with a single ASM at low dose and titrate
- Failure of two appropriately chosen and dosed ASMs defines drug-resistant epilepsy (~30% of patients)
Drug-Resistant Epilepsy
- Surgical evaluation is the 1st-line treatment for drug-resistant focal epilepsy
- Most common surgery: Anterior temporal lobectomy (for mesial TLE)
- Other surgical options: Corpus callosotomy (drop attacks), hemispherectomy
- Neuromodulation: Vagus nerve stimulation (VNS), responsive neurostimulation (RNS), deep brain stimulation (DBS - anterior nucleus of thalamus)
- Ketogenic diet: High-fat, low-carbohydrate; especially useful in pediatric drug-resistant epilepsy
Stopping ASMs
- Typically considered after 2 years seizure-free
- EEG guides decision - normal EEG = better prognosis
- Gradual taper over weeks-months
- Discuss driving implications
8. Status Epilepticus (SE)
Definition: Seizure lasting ≥5 minutes, OR two or more seizures without full recovery between them.
Convulsive SE lasting >30 min carries mortality up to 20%.
Most Common Cause
- Non-compliance with ASM (most common cause of tonic-clonic SE)
Management Protocol (Time-Critical)
0-5 min: ABCs, IV access, O2, glucose, vitals, bloods
Benzodiazepine (FIRST-LINE):
- IV Lorazepam 0.1 mg/kg (drug of FIRST choice in hospital)
- IM Midazolam (out-of-hospital or no IV access)
- Rectal Diazepam (community)
5-20 min: If seizure continues → SECOND-LINE:
- IV Levetiracetam, OR
- IV Valproate, OR
- IV Phenytoin/Fosphenytoin
20-40 min: If refractory SE → THIRD-LINE:
- Anaesthetic doses: Propofol, Thiopental, Midazolam infusion
- ICU admission, EEG monitoring
Super-refractory SE (>24h despite anaesthesia):
- Ketamine, Ketogenic diet, Immunotherapy
Plum and Posner's Diagnosis and Treatment of Stupor and Coma; Swanson's Family Medicine Review
9. Special Situations
Epilepsy in Pregnancy
- Discuss contraception - enzyme-inducing ASMs (phenytoin, carbamazepine, phenobarbital) reduce efficacy of oral contraceptives
- Valproate has highest teratogenic risk (10x neural tube defects, neurodevelopmental effects) - avoid if possible
- Lamotrigine and levetiracetam are preferred in pregnancy
- Folic acid supplementation (5 mg/day) for all women on ASMs planning pregnancy
- AAN/AES 2024 Practice Guideline (PMID: 38748979): confirms teratogenesis risk hierarchy and recommends shared decision-making
Sudden Unexpected Death in Epilepsy (SUDEP)
- Leading cause of epilepsy-related death
- Rate: ~1 in 1000 person-years; higher in drug-resistant epilepsy
- Mechanism: Postictal cardiorespiratory failure, possibly postictal generalized EEG suppression
- Risk reduction: Better seizure control, avoid nocturnal seizures, use of safety pillows
Non-Epileptic Attack Disorder (NEAD / PNES)
- Psychogenic non-epileptic seizures (PNES) - must be distinguished from epilepsy
- Often present with motor seizures but no EEG correlate
- Video-EEG monitoring is the gold standard for diagnosis
10. Exam High-Yield Summary
| Topic | Key Fact |
|---|
| ILAE 2014 definition | 2 unprovoked seizures, OR 1 seizure with ≥60% recurrence risk |
| Single seizure rule | "A single seizure does not epilepsy make" |
| 3 Hz spike-wave EEG | Childhood absence epilepsy |
| Hypsarrhythmia | West syndrome (infantile spasms) |
| Na⁺ channel blockers WORSEN | Dravet syndrome (SCN1A mutation) |
| 1st choice for absence only | Ethosuximide |
| 1st choice SE (IV) | Lorazepam |
| Teratogen with highest risk | Valproate |
| Drug-resistant epilepsy defined by | Failure of 2 adequate trials of ASMs |
| Most common adult focal epilepsy | Mesial temporal lobe epilepsy (hippocampal sclerosis) |
| JME characteristic time | Morning myoclonic jerks after waking |
| Vigabatrin irreversible toxicity | Visual field loss (bilateral) |
| Surgery for drug-resistant focal | Anterior temporal lobectomy |
Sources: Bradley and Daroff's Neurology in Clinical Practice; Eric Kandel, Principles of Neural Science, 6th Ed.; Adams and Victor's Principles of Neurology, 12th Ed.; AAN/AES Practice Guideline 2024 (PMID: 38748979)